Science AI Journal
Medicine · Research topic

Open research questions in Liver physiology and pathology

182 gap statements mined from Liver physiology and pathology papers in our 4.5M-paper local library, which holds 859 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Liver physiology and pathology? See the ranked Medicine journals.

What the literature leaves open

  • The traditional view of liver cirrhosis as the linear accumulation of extracellular matrix is insufficient to explain the stagnation of fibrosis reversal and the persistent risk of hepatocellular carcinoma. A new understanding of liver cirrhosis is needed to address these challenges.

    Liver cirrhosis and hepatocellular carcinoma: chronological decoupling of biochemical clearance and mechanical regeneration signals a systems biology hypothesis on programed deconstruction failure · 2026 · DOI

  • The lack of effective treatments for liver fibrosis. The limited understanding of the mechanisms by which the gut microbiome influences liver disease.

    Pharmabiotics, Phocaeicola dorei, ameliorates cholestatic liver fibrosis by alleviating macrophage efferocytosis of neutrophils · 2026 · DOI

  • The active components and molecular targets of Yiguanjian for liver fibrosis are unclear. The causal relationship between feature genes and liver fibrosis is unclear.

    Core Active Ingredients and Therapeutic Targets of Yiguanjian for Liver Fibrosis: A Computational and Genetic Inference-based Study · 2026 · DOI

  • However, the specific biological functions of GSTM3 in liver fibrosis, particularly in spontaneous fibrosis reversal, remain unknown.

    GSTM3 Knockdown Promotes Liver Fibrosis Reversal by Inhibiting Hepatic Stellate Cell Activation via PPARγ Signaling · 2026 · DOI

  • The lack of effective therapeutic strategies for MASH. The need for novel therapeutic approaches to alleviate MASH.

    Engineered Ti₃C₂ MXene nanosystems for macrophage-targeted therapy of metabolic dysfunction-associated steatohepatitis · 2026 · DOI

  • Saikosaponin-d (SSd) has demonstrated antifibrotic effects, but its impact on the transforming growth factor-β1 (TGF-β1)/Smads signaling pathway and epithelial-mesenchymal transition (EMT) during fibrosis remains poorly understood.

    Saikosaponin-d alleviates hepatic stellate cell activation and liver fibrosis by inhibiting the TGF-β1/Smads signaling pathway and blocking the EMT process · 2026 · DOI

  • The study only analyzed a limited number of datasets. The experimental design only included a CCl4-induced mouse model and human LX-2 hepatic stellate cells.

    Identification of mitochondria-related biomarkers in liver fibrosis via interpretable machine learning and WGCNA: transcriptomic analysis and In Vivo validation · 2026 · DOI

  • Further studies are needed to validate the findings and explore the therapeutic potential of ACOT9. The use of other machine learning algorithms and experimental designs to identify key genes associated with liver fibrosis. The study of other diseases related to mitochondria dysfunction.

    Identification of mitochondria-related biomarkers in liver fibrosis via interpretable machine learning and WGCNA: transcriptomic analysis and In Vivo validation · 2026 · DOI

  • The lack of non-invasive diagnostic tests for hepatic fibrosis. The need for improved diagnosis and treatment of MASLD. The potential of cell-free DNA methylation signatures as biomarkers for liver fibrosis in MASLD.

    Plasma PDGFRß and PSD4 methylation levels for non-invasive staging of liver fibrosis · 2026 · DOI

  • Steatotic liver disease is a heterogeneous group of chronic liver disorders with diverse pathophysiological drivers and variable clinical outcomes. Conventional histopathology lacks the resolution to capture spatial and mechanistic nuances of the disease. Patients are exposed to differing constellations of metabolic stress, alcohol-related toxicity, and inflammatory signaling.

    AI redefines fibrosis patterns in steatotic liver disease: Opportunities and challenges · 2026 · DOI

  • Liver fibrosis is a major health problem with limited effective medical therapies. The underlying pathogenic mechanisms of fibrosis are not fully understood. The development of new therapeutic strategies for liver fibrosis is challenging.

    NRP1 promotes hepatic fibrosis by regulating Src/Rab7-mediated lysosomal degradation of TβRI · 2026 · DOI

  • While cellular continuity between hepatically licensed T cells and specific CNS lesions remains to be established, the combined evidence across epidemiological, neuropathological, and preclinical studies is sufficient to define a mechanistic framework and act on it therapeutically.

    Hepatosystemic T cell licensing in MASLD-associated neuroinflammation · 2026 · DOI

  • The mechanism of TGF-β1/TGFβRI/Smad pathway in hepatic fibrosis cysts formation is not fully understood. There is a need for effective therapeutic agents for the treatment of hepatic fibrosis cysts.

    Effect of LY2109761 on TGF-β1/TGFβRI/Smad Pathway and Hepatic Fibrosis Cysts Formation in Rats Infected with Echinococcus granulosus: an In Vitro and In Vivo Study · 2026 · DOI

  • ITGBL1 was previously thought to be related to integrin regulation and TGF-β signaling pathway (34), its exact effect on liver fibrosis remains unclear.

    ITGBL1-MYH9 interaction in hepatic stellate cells acts as a mechano-regulator controlling liver fibrosis in mice · 2026 · DOI

  • The mechanisms of how LPCs rapidly proliferate and differentiate into hepatocytes remain largely unknown. The role of TGF-β in regulating LPC quiescence and activation is not well understood.

    TGF-β serves as a critical signaling determinant of liver progenitor cell activation and function · 2026 · DOI

  • This strategy remains constrained by limited druggability, compensatory signaling networks, and challenges in achieving precise, tissue‑specific delivery, particularly for RNA‑ and gene‑editing‑based approaches.

    Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review) · 2026 · DOI

  • The early pathways linking hepatocellular stress to tissue integrity remain incompletely defined. The mechanisms by which hepatocyte Smo activation attenuates liver injury are not well understood. The role of Vegfa in APAP-induced liver injury is not fully elucidated.

    Hepatocyte Hedgehog activation attenuates acetaminophen-induced liver injury through a Vegfa-associated vascular response · 2026 · DOI

  • Leveraging spatial tissue analytics to inform individualized, integrated management may represent one of the most impactful directions for research and clinical care.

    AI redefines fibrosis patterns in steatotic liver disease: Opportunities and challenges · 2026 · DOI

  • Although, to the best of our knowledge, there are no reports on the direct interaction between GSS and circadian clock genes, studies have indicated that GSS reduces ROS via the Nrf2 signaling pathway and ROS has been proven to disrupt BMAL1/CLOCK oscillations (53), suggesting that its anti‑fibrotic effects may be partially related to the restoration of redox rhythms.

    Ginsenosides alleviate the progression of hepatic fibrosis by targeting the liver circadian clock gene CLOCK · 2026 · DOI

  • Further study of the 'Chronological Decoupling' hypothesis and its implications for liver cirrhosis. Investigation of the potential therapeutic applications of 'Protocol Resynchronization' therapy. Exploration of the role of LOXL2 in ECM cross-linking and its potential as a therapeutic target.

    Liver cirrhosis and hepatocellular carcinoma: chronological decoupling of biochemical clearance and mechanical regeneration signals a systems biology hypothesis on programed deconstruction failure · 2026 · DOI

  • Further validation of the diagnostic performance of the five key genes in a more strictly defined cohort of early-stage liver fibrosis. Investigation of the therapeutic potential of Yiguanjian for liver fibrosis.

    Core Active Ingredients and Therapeutic Targets of Yiguanjian for Liver Fibrosis: A Computational and Genetic Inference-based Study · 2026 · DOI

  • Further investigation of MMCT's therapeutic potential in MASH treatment. Exploration of MMCT's applications in other inflammatory diseases. Evaluation of MMCT's long-term biosafety and efficacy in clinical settings.

    Engineered Ti₃C₂ MXene nanosystems for macrophage-targeted therapy of metabolic dysfunction-associated steatohepatitis · 2026 · DOI

  • Further mechanistic investigation is needed to understand the effects of e-cigarette vaping on human health, - Studies should examine the long-term effects of e-cigarette vaping on various organ…

    E-cigarette vaping is associated with pro-fibrotic gene expression in kidney and liver tissues · 2026 · DOI

  • Studying the vascular-focused direction for acute liver failure, - Investigating the role of Vegfa in APAP-induced liver injury, - Examining the effects of Smo activation on liver injury in other…

    Hepatocyte Hedgehog activation attenuates acetaminophen-induced liver injury through a Vegfa-associated vascular response · 2026 · DOI

  • The study uses a mouse model, - The study has a limited sample size, - The study does not investigate the long-term effects of PDE3B deficiency or pharmacological PDE3…

    PDE3B as a multi-organ therapeutic node in the gut–liver axis of metabolic dysfunction-associated steatohepatitis · 2026 · DOI

Most-cited papers in Liver physiology and pathology

Most recent work

Find a gap in your own Liver physiology and pathology sub-topic

This page shows what the Liver physiology and pathology literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 4.5M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,304 open questions
Substance Abuse Treatment and Outcomes
1,956 open questions
Dementia and Cognitive Impairment Research
1,232 open questions
Ferroptosis and cancer prognosis
1,146 open questions
Liver Disease Diagnosis and Treatment
1,049 open questions
Smoking Behavior and Cessation
1,025 open questions
Physical Activity and Health
1,002 open questions
Attention Deficit Hyperactivity Disorder
982 open questions
Open questions raised by papers listed on this page include: (1) A new understanding of liver cirrhosis is needed to address these challenges (“Liver cirrhosis and hepatocellular carcinoma: chronological decoupling of…”, 2026); (2) The active components and molecular targets of Yiguanjian for liver fibrosis are unclear (“Core Active Ingredients and Therapeutic Targets of Yiguanjian for Liver…”, 2026); (3) The specific biological functions of GSTM3 in liver fibrosis, particularly in spontaneous fibrosis reversal, remain unknown (“GSTM3 Knockdown Promotes Liver Fibrosis Reversal by Inhibiting Hepatic Stellate…”, 2026); (4) Saikosaponin-d (SSd) has demonstrated antifibrotic effects, but its impact on the transforming growth factor-β1 (TGF-β1)/Smads signaling pathway and epithelial-mesenchymal transition (EMT) during fibrosis remains poorly understood (“Saikosaponin-d alleviates hepatic stellate cell activation and liver fibrosis…”, 2026); (5) Further studies are needed to validate the findings and explore the therapeutic potential of ACOT9 (“Identification of mitochondria-related biomarkers in liver fibrosis via…”, 2026). 182 gap statements have been mined from Liver physiology and pathology papers in our 4.5M-paper local library, which holds 859 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.